Research programme: small molecule therapeutics - Incozen/Rhizen

Drug Profile

Research programme: small molecule therapeutics - Incozen/Rhizen

Alternative Names: RP 3120; RP 3163; RP 5090; RP 6557; RP-6503

Latest Information Update: 20 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incozen Therapeutics
  • Developer Incozen Therapeutics; Rhizen Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Calcium channel antagonists; Immunomodulators; Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Immunological disorders; Lung disorders
  • No development reported Hypersensitivity; Lupus vulgaris; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 20 Oct 2016 Preclinical development is ongoing for Lung disorders in Switzerland (Rhizen Pharmaceuticals pipeline, October 2016)
  • 20 Oct 2016 Preclinical trials in Immunological disorders in Switzerland (PO) (Rhizen Pharmaceuticals pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Allergy in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top